Table 1: Demographic and ocular clinical features and treatment properties at the time of blood sampling of patients with Behçet uveitis.

Patient No.	Age/ gender	Age at ocular involvement	Feature of uveitis	AZA and maintenance systemic corticosteroid dose / duration	Maintenance dose of IFN a-2a and systemic corticosteroid dose / duration
1.	21/M	19	Panuveitis OU, vitritis OU, retinal vasculitis OU, retinitis OU, macular edema OU	3mg/kg/day AZA, 8mg/kg/day ster, 3 mo.	4.5 million IU 3x/week, no ster, 6 mo.
2.	29/M	23	Panuveitis OU, vitritis OU, retinal vasculitis OU, retinitis OU, macular edema (OS)	2mg/kg/day AZA, 8mg/kg/day ster, 3 mo.	4.5 million IU 3x/week, 8 mg/kg/day ster, 5 mo.
3.	54/F	29	Panuveitis OU, vitritis OU, retinal vasculitis OU	2mg/kg/day AZA, no ster, 3 mo.	3 million IU 3x/week, no ster, 6 mo.
4.	29/M	21	Panuveitis OU, vitritis OU, retinal vasculitis OU, retinitis OU	2mg/kg/day AZA, 8mg/kg/day ster, 7 mo.	4.5 million IU 3x/week, 8 mg/kg/day ster, 4 mo.
5.	34/F	32	Panuveitis OU, vitritis OU, retinal vasculitis OU, macular edema OU	2mg/kg/day AZA, no ster, 4 mo.	4.5 million IU 3x/week, no ster, 6 mo.

F: Female, M: Male, AZA: Azathioprine, IFN a-2a: Interferon alfa-2a, OU: Bilateral, OD: Right Eye, OS: Left Eye, IU: International Units, ster: Systemic corticosteroid, methyl-prednisolone